Teva Reports Second Quarter 2022 Financial Results
Teva has reached agreement in principle on the primary financial terms of a nationwide opioids settlement and has revised its provision to reflect its terms Key financial highlights and outlook Revenues of $3.8 billion GAAP diluted loss per share of $0.21 Non-GAAP diluted EPS of $0.68 Cash flow generated from operating activities of $123 million … [Read more…]